Vorinostat
- Generic Name
- Vorinostat
- Brand Names
- Zolinza
- Drug Type
- Small Molecule
- Chemical Formula
- C14H20N2O3
- CAS Number
- 149647-78-9
- Unique Ingredient Identifier
- 58IFB293JI
- Background
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase...
- Indication
用于治疗加重、持续和复发或用两种全身性药物治疗后无效的T细胞淋巴瘤(CTCL, 一种非霍奇金淋巴瘤)。
- Associated Conditions
- Cutaneous T-Cell Lymphoma Recurrent, Persistent Cutaneous T-Cell Lymphoma, Progressive Cutaneous T-cell lymphoma
- Associated Therapies
- -
Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2012-05-08
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 9
- Registration Number
- NCT01593670
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
- Conditions
- Interventions
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT01587352
- Locations
- 🇺🇸
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
- Conditions
- Adult B Acute Lymphoblastic LeukemiaAdult T Acute Lymphoblastic LeukemiaAnaplastic Large Cell LymphomaAngioimmunoblastic T-Cell LymphomaIntraocular LymphomaRecurrent Adult Burkitt LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Mycosis Fungoides and Sezary SyndromeChronic Lymphocytic LeukemiaHepatosplenic T-Cell Lymphoma
- Interventions
- First Posted Date
- 2012-03-30
- Last Posted Date
- 2018-04-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 34
- Registration Number
- NCT01567709
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2012-03-09
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Steven E. Coutre
- Target Recruit Count
- 23
- Registration Number
- NCT01550224
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 282
- Registration Number
- NCT01522976
- Locations
- 🇺🇸
Rose Medical Center, Denver, Colorado, United States
🇺🇸Western States Cancer Research NCORP, Denver, Colorado, United States
🇺🇸Mercy Medical Center, Durango, Colorado, United States
Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy
- Conditions
- Interventions
- First Posted Date
- 2011-12-29
- Last Posted Date
- 2016-05-10
- Lead Sponsor
- Tiziana Marangon
- Registration Number
- NCT01501370
- Locations
- 🇮🇹
Clinica di Ematologia, A.O.U. Ospedali Riuniti, Ospedale Umberto I di Ancona, Ancona, Italy
🇮🇹U.O.S. di Ematologia, Ospedale Mazzoni, Ascoli Piceno, Italy
🇮🇹Dh ematologia, A.O.U. Careggi, Firenze, Italy
Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2011-12-15
- Last Posted Date
- 2012-05-11
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Registration Number
- NCT01492881
- Locations
- 🇺🇸
Lineberger Comphrehensive Cancer Center at University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2020-10-27
- Target Recruit Count
- 23
- Registration Number
- NCT01483690
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇦🇺Children's Hospital at Westmead, Westmead, New South Wales, Australia
🇦🇺Sydney Children's Hospital, Sydney, Australia
Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
- First Posted Date
- 2011-08-22
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 78
- Registration Number
- NCT01421173
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2011-08-10
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 23
- Registration Number
- NCT01413750
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Southern Illinois University School of Medicine, Springfield, Illinois, United States
🇺🇸Mercy Hospital Saint Louis, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.